Guided Therapeutics (GTHP) Total Non-Current Liabilities (2016 - 2025)
Guided Therapeutics (GTHP) has disclosed Total Non-Current Liabilities for 13 consecutive years, with $694000.0 as the latest value for Q4 2025.
- Quarterly Total Non-Current Liabilities rose 519.64% to $694000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $694000.0 through Dec 2025, up 519.64% year-over-year, with the annual reading at $694000.0 for FY2025, 519.64% up from the prior year.
- Total Non-Current Liabilities hit $694000.0 in Q4 2025 for Guided Therapeutics, up from $79000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.8 million in Q4 2021 to a low of $35000.0 in Q2 2025.
- Historically, Total Non-Current Liabilities has averaged $870950.0 across 5 years, with a median of $710500.0 in 2023.
- Biggest five-year swings in Total Non-Current Liabilities: tumbled 90.6% in 2024 and later surged 519.64% in 2025.
- Year by year, Total Non-Current Liabilities stood at $1.8 million in 2021, then fell by 22.95% to $1.4 million in 2022, then plummeted by 51.74% to $666000.0 in 2023, then crashed by 83.18% to $112000.0 in 2024, then soared by 519.64% to $694000.0 in 2025.
- Business Quant data shows Total Non-Current Liabilities for GTHP at $694000.0 in Q4 2025, $79000.0 in Q3 2025, and $35000.0 in Q2 2025.